Abstract
It is well established that an increase of n-6 polyunsaturated (i.e. arachidonic and arachidonic-converted linoleic acids) fat dietary intake enhances carcinogenesis and promotes tumorigenesis through oxidative metabolism. The Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes mediate the oxidative metabolism of n-6 polyunsaturated fatty acids and generate a cascade of biological active molecules. Nonsteroidal antinflammatory drugs (NSAIDs) modulating arachidonic acid (AA) metabolism have been utilized in cancer chemoprevention. The gastrolesivity of a prolonged use of nonselective NSAIDs, due to the COX inhibition, an important housekeeping gene of the gastrointestinal system, contraindicated their use in chemoprevention. Moreover, cardiovascular side effects emerged in the long-term use of COX-2 specific inhibitors rising doubts on their use for cancer chemoprevention. This evidence renewed the interest into other AA-metabolizing pathways relevant in inflammation and carcinogenesis. Here, the role of the LOXs pathways in carcinogenesis is reviewed. Inhibition of the LOX pathways, alone or in association with COX-2 pathway, appears to be a promising field for detecting new molecular target and engineering new chemopreventive strategies on cancer.
Keywords: Lipoxygenase inhibitors, cancer prevention, cellular senescence
Current Pharmaceutical Design
Title: Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Volume: 16 Issue: 6
Author(s): Cecilia Menna, Fabiola Olivieri, Alfonso Catalano and Antonio Procopio
Affiliation:
Keywords: Lipoxygenase inhibitors, cancer prevention, cellular senescence
Abstract: It is well established that an increase of n-6 polyunsaturated (i.e. arachidonic and arachidonic-converted linoleic acids) fat dietary intake enhances carcinogenesis and promotes tumorigenesis through oxidative metabolism. The Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes mediate the oxidative metabolism of n-6 polyunsaturated fatty acids and generate a cascade of biological active molecules. Nonsteroidal antinflammatory drugs (NSAIDs) modulating arachidonic acid (AA) metabolism have been utilized in cancer chemoprevention. The gastrolesivity of a prolonged use of nonselective NSAIDs, due to the COX inhibition, an important housekeeping gene of the gastrointestinal system, contraindicated their use in chemoprevention. Moreover, cardiovascular side effects emerged in the long-term use of COX-2 specific inhibitors rising doubts on their use for cancer chemoprevention. This evidence renewed the interest into other AA-metabolizing pathways relevant in inflammation and carcinogenesis. Here, the role of the LOXs pathways in carcinogenesis is reviewed. Inhibition of the LOX pathways, alone or in association with COX-2 pathway, appears to be a promising field for detecting new molecular target and engineering new chemopreventive strategies on cancer.
Export Options
About this article
Cite this article as:
Menna Cecilia, Olivieri Fabiola, Catalano Alfonso and Procopio Antonio, Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks, Current Pharmaceutical Design 2010; 16 (6) . https://dx.doi.org/10.2174/138161210790883822
DOI https://dx.doi.org/10.2174/138161210790883822 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism On Electromagnetic Ablation of Biological Tissues: A Review
Recent Patents on Electrical Engineering Editorial (Thematic Issue: Management of Gynaecological Cancers - An Update)
Reviews on Recent Clinical Trials Pharmacokinetics and Disposition of Nanomedicine Using Biodegradable PEG/PCL Polymers as Drug Carriers
Current Drug Metabolism Evidence-Based Management of Infertile Couples with Repeated Implantation Failure Following IVF
Current Women`s Health Reviews The p53-Estrogen Receptor Loop in Cancer
Current Molecular Medicine <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry A Salicylic Acid-Based Analogue Discovered from Virtual Screening as a Potent Inhibitor of Human 20α-Hydroxysteroid Dehydrogenase
Medicinal Chemistry Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Chemical and physical factors influencing the dynamics of differentiation in embryonic stem cells
Current Stem Cell Research & Therapy Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Drug Target Strategies in Breast Cancer Treatment: Recent Developments
Anti-Cancer Agents in Medicinal Chemistry Selective Estrogen Receptor Modulators (SERMs): Effects on Multiple Organ Systems
Current Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets